Assessing the impact of nocturia on health-related quality of life and utility: results of an observational survey in adults

The impact of nocturia (getting up at night to void) on health-related quality of life (HRQoL) is often underestimated. We investigated the relative burden in terms of HRQoL and utilities of nocturia in a real-world setting.

Patient data were collected from two surveys: a nocturia-specific, cross-sectional survey of physicians and their patients (DSP®), and a general UK population health survey (HSFE). Utilities (EQ-5D-5L), productivity (Work Productivity and Activity Index) and the impact of nocturia symptoms (Nocturia Impact Diary and Overactive Bladder Questionnaires) were assessed against the number of voids. A robust linear regression model with propensity score weights was used to control for confounding factors in estimating utilities.

Physician-recorded data were available from 8,738 patients across the USA, Germany, Spain, France and UK; of these, 5,335 (61%) included patient-reported outcomes. 6,302 controls were drawn from the two surveys and compared to 1,104 nocturia patients. Deterioration of HRQoL was associated with increasing number of night-time voids (p < 0.0001). In particular, significant differences were observed between 0-1 and ≥2 voids (p < 0.001). The regression model demonstrated that nocturia (≥2 per night) is associated with a modest but significant deterioration in utility of 0.0134 (p < 0.05).

The cause of nocturia is multifactorial and the mostly elderly patients may have several concomitant diseases. We tried to adjust for the most common ones but there may be diseases or unknown relationships we have not included.

Nocturia negatively affected HRQoL and patient utility. A clear effect is seen already at two voids per night and for HRQoL. Every effort should therefore be made to reduce nocturia below the bother threshold of two voids per night.

Journal of medical economics. 2016 Jul 07 [Epub ahead of print]

Fredrik Andersson, Peter Anderson, Tove Holm-Larsen, James Piercy, Karel Everaert, Tim Holbrook

a Ferring Pharmaceuticals A/S , Kay Fiskers Plads 11, DK-2300 Copenhagen , Denmark., c Adelphi Real World, Adelphi Mill , Bollington, Cheshire, SK10 5JB , Manchester , UK., d Pharma Evidence , Sommervej 9, DK-3520 Farum , Denmark., c Adelphi Real World, Adelphi Mill , Bollington, Cheshire, SK10 5JB , Manchester , UK., e Department of Urology , Ghent University Hospital , De Pintelaan 185 P3, 9000 Ghent , Belgium., c Adelphi Real World, Adelphi Mill , Bollington, Cheshire, SK10 5JB , Manchester , UK.